MedTrace Logo

Composite Ratios Boost CRP's Power in Monitoring Ulcerative Colitis.

NCT07261579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-01-21

No results posted yet for this study

Summary

Inflammatory Bowel Disease (IBD) is a chronic, recurrent condition marked by disturbed levels of various hematological inflammatory cells and a deregulated immune environment. While C-reactive protein (CRP) is a key acute-phase reactant, its high levels can persist even after inflammation subsides. Other simple, cost-effective ratios, such as the Neutrophil-to-Lymphocyte Ratio (NLR), the Platelet-to-Lymphocyte Ratio (PLR), and Albumin-related ratios, also serve as promising, reproducible markers of systemic inflammation reflecting both immune status and nutrition. This study's objective is to evaluate the diagnostic performance of these various hematological inflammatory cellular components and CRP-related ratios (like the CAR) as predictors for Ulcerative Colitis (UC) disease severity, using colonoscopic and microscopic findings as the gold standard for comparison.

Conditions

Interventions

DIAGNOSTIC_TEST

C-Reactive Protein measuring CRP

5-ml peripheral blood samples were aseptically obtained for a complete blood count, and ELISA estimation of serum CRP

DIAGNOSTIC_TEST

CRP to Albumin Ratio

Serum CRP to albumin ratio (CAR) is a combination of markers for systemic inflammation and nutritional status

Sponsors & Collaborators

  • Benha University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2025-11-25
Completion
2025-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07261579 on ClinicalTrials.gov